Article Text

Download PDFPDF

182 Xenium in situ analysis and reproducibility study of multiple carcinomas for clinical studies
  1. Tong Lu1,
  2. Rikita Gakhar1,
  3. Elim Cheung1,
  4. Lutong Zhang1,
  5. Wanqiu Zhang2,
  6. Thao Tran2,
  7. Alice Ly3,
  8. Baruch Berger2,
  9. Nico Verbeeck2,
  10. Heath Patterson2,
  11. Marc Claesen2 and
  12. Vidyodhaya Sundaram1
  1. 1BioChain Institute Inc., Newark, CA, USA
  2. 2Aspect Analytics NV, Genk, Limburg, Belgium
  3. 3Aspect Analytics NV, Genk, Belgium
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.

Abstract

Background 10x Genomics Xenium assay is the newest in situ spatial transcriptomics platform offering sub-cellular resolution in frozen and FFPE tissue sections for a deeper study of cellular mechanisms and interactions. Mapping RNA targets at high specificity with fully customizable assays and quick workflow, it uses rolling circle amplification and interpretation-ready data is available immediately after the run. At BioChain Institute, Inc. (BioChain), we are conducting validation studies for reproducibility of results with the Xenium platform using BioChain’s oncology biospecimen.

Methods FFPE tumor tissues from BioChain’s biorepository were screened by our pathologist for tumor content above 30%. Four carcinoma tissues from human breast, colon, lung, and kidney with high DV200 scores were selected. A tissue array was constructed with these tissues to place within the Xenium slide’s imageable area. Two serial sections were used in Xenium assay, which were performed according to the 10x Genomics’ protocol by different operators independently. The pre-designed Human Multi-Tissue and Cancer Panel was used for targeting 377 genes. The Post-Xenium H&E staining and imaging was performed, and the H&E image was integrated with the DAPI image using Xenium Explorer. Further computational analysis was performed by Aspect Analytics to compare the data between the serial sections.

Results The results were found to be reproducible between two different operators. For example, in the breast section, over 96,000 cells were detected and median transcripts per cell were 70 in both the runs (figure 1). There were 20 clusters representing different cell types/states, 99% transcripts were within cells, and ~85% of the transcripts were found to be high quality. Pearson coefficient between the serial sections data showed positive correlation (figure 2).

Conclusions Xenium platform is a powerful tool for the subcellular spatial transcriptomics study of tissues with targeted gene panels.

Consent All samples used in the study were donor consented, de-identified, and IRB approved.

Abstract 182 Figure 1

Xenium Explorer images of the two Breast serial sections at K-2 means clustering showing similar expression distribution across the two sections

Abstract 182 Figure 2

Correlation curve between the Breast carcinoma serial sections’ Xenium datasets, showing positive correlation

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.